AI
ALNY icon

Atom Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Atom Investors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,800
Closed -$1.17M – 468
2024
Q2 		$1.17M Buy
4,800
+663
+16% +$105K 0.12% 226
2024
Q1 		$618K Buy
+4,137
New +$690K 0.08% 297
2023
Q2 		– Sell
-7,533
Closed -$1.51M – 292
2023
Q1 		$1.51M Buy
7,533
+6,135
+439% +$1.29M 0.82% 25
2022
Q4 		$332K Sell
1,398
-5,289
-79% -$1.13M 0.17% 127
2022
Q3 		$1.34M Sell
6,687
-228
-3% -$43.5K 0.47% 60
2022
Q2 		$1.01M Buy
+6,915
New +$981K 0.44% 66

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Atom Investors's ALNY Position: Q3 2024 in Review

Atom Investors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 4,800 shares — an estimated $1.17M sold.

Atom Investors first reported a position in ALNY in Q2 2022 and held it in 6 quarters. The position peaked at $1.51M in Q1 2023. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

  • Atom Investors reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Atom Investors sold 4,800 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $1.17M.
  • Atom Investors first reported a position in Alnylam Pharmaceuticals in Q2 2022 and held it in 6 quarters.
  • Atom Investors's Alnylam Pharmaceuticals position peaked at $1.51M in Q1 2023.
  • 567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Atom Investors's 13F filing for Q3 2024, filed 14 Nov 2024.